Is Now a Good Time to Buy This Biotech Stock?

To say that biotech Bluebird Bio (NASDAQ: BLUE) has significantly lagged the market in the past year would be an understatement. Shares of the gene-editing focused company have dropped by 89% in the trailing 12-month period, primarily due to various regulatory headwinds.

However, Bluebird recently received some good news that may signal a comeback is in the cards for the biotech. With this backdrop in mind, let's find out whether now is a good time to get in on Bluebird.

Continue reading

Source Fool.com